Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interim analyses].

Andrew Kramar1, Xavier Paoletti

  • 1Unité de Biostatistiques, Centre régional de lutte contre le cancer Val d'Aurelle-Paul Lamarque, Montpellier. Andrew.Kramar@valdorel.fnclcc.fr

Bulletin Du Cancer
|December 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same author

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same author

HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial.

BMJ open·2026
Same author

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis.

Gynecologic oncology·2025
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

This article details planning interim analyses for phase III clinical trials, covering superiority, non-inferiority, and futility. It clarifies the role of Data Monitoring Committees with examples for better trial planning.

Area of Science:

  • Clinical Trials Methodology
  • Statistical Analysis in Clinical Research
  • Pharmaceutical Development

Context:

  • Phase III clinical trials require robust planning for interim analyses.
  • Ensuring trial integrity and ethical conduct is paramount.
  • Data Monitoring Committees play a crucial role in trial oversight.

Purpose:

  • To present methodological principles for planning interim analyses in phase III trials.
  • To summarize the cases for superiority, non-inferiority, and futility.
  • To elucidate the functions of Data Monitoring Committees.

Summary:

  • Methodological principles for interim analyses in phase III clinical trials are outlined.
  • The article discusses statistical considerations for superiority, non-inferiority, and futility.

Related Experiment Videos

  • Examples are provided to aid investigator understanding and planning.

    • Impact:

    • Improved understanding and planning of interim analyses for phase III trials.
    • Enhanced decision-making during clinical trial conduct.
    • Facilitation of efficient and ethical clinical trial management.